Drugs / Silgard
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Silgard | — | 2019-02-18 | europa.eu ↗ |
| Approved | EU (EMA) | Silgard | — | 2006-09-19 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01375868 | Oct 2011 → Dec 2018 | larynx squamous papilloma | Ruth Tachezy, PhD. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Silgard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01375868 ↗ |
| Modality | Vaccine | “tetravalent antiviral vaccine” NCT01375868 ↗ |